Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma. (2018)

• Record Type: Journal Article
• Authors: Satoh, Shingo; Shiroyama, Takayuki; Tamiya, Motohiro; Nasu, Shingo; Tanaka, Ayako; Morita, Satomu; Morishita, Naoko; Suzuki, Hidekazu; Okamoto, Norio; Hirashima, Tomonori
• Is Part Of: Respiratory medicine case reports. Volume 23(2018)
• Page Start: 68
• Page End: 70
• Publication Date: 2018
• Subjects: Osimertinib -- Pneumonitis -- Rechallenge -- Corticosteroid; EGFR epidermal growth factor receptor -- CT computed tomography -- GGO ground-glass opacity; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2017.12.005
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rechallenge after EGFR-TKI-induced pneumonitis have been reported, little is known about post-pneumonitis osimertinib rechallenge. We describe a 69-year-old never-smoking Japanese woman with postoperative recurrent lung adenocarcinoma retreated with osimertinib after osimertinib-induced pneumonitis. Although osimertinib rechallenge must be carefully chosen based on risk/benefit analysis, osimertinib rechallenge after osimertinib-induced pneumonitis may be an option, with limited alternative therapeutic options.